Neurologists’ perceptions about the readiness for implementing anti‐amyloid drugs for Alzheimer's disease in Peru
For the introduction of monoclonal antibodies for AD to be feasible in Peru, modifications to the functioning of healthcare institutions are required, emphasizing the need for strategic healthcare planning.
Authors
- José Carlos Huilca (ORCID: https://orcid.org/0000-0001-5561-4702)
- Diego Bustamante‐Paytan (ORCID: https://orcid.org/0000-0002-1073-1961)
- Marco Malaga
- Belén Custodio (ORCID: https://orcid.org/0009-0007-1445-7211)
- Graciet Verastegui
- Diego Chambergo‐Michilot
- William Bayona
- Nilton Custodio
- Mayra Rojas
- Rosa Montesinos
- Isabel Camargo
- Katherine Agüero‐Flores
Institutions
- Universidad de Lima (PE)
- Universidad Científica del Sur (PE)
- National University of Trujillo (PE)
- Private University of Trujillo (PE)
- Forum Solidaridad Perú (PE)
- Institute of Peruvian Studies (PE)
- Universidad Católica San Pablo (PE)
- Universidad Andina del Cusco (PE)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/alz70860_105685
- Primary Topic
- Alzheimer's disease research and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00